BROADWOOD CAPITAL INC - Q1 2018 holdings

$688 Million is the total value of BROADWOOD CAPITAL INC's 9 reported holdings in Q1 2018. The portfolio turnover from Q4 2017 to Q1 2018 was 10.0% .

 Value Shares↓ Weighting
MNST SellMONSTER BEVERAGE CORP NEW$273,104,000
-10.1%
4,773,708
-0.5%
39.68%
-6.2%
STAA  STAAR SURGICAL CO$160,657,000
-4.5%
10,855,1790.0%23.34%
-0.5%
BTX  BIOTIME INC$80,623,000
+25.1%
29,971,5610.0%11.71%
+30.4%
IWM  ISHARES TRrussell 2000 etf$63,769,000
-0.4%
420,0000.0%9.26%
+3.8%
MNST BuyMONSTER BEVERAGE CORP NEWput$45,768,000
+44.6%
800,000
+60.0%
6.65%
+50.7%
AXON BuyAXON ENTERPRISE INC$29,878,000
+188.3%
760,062
+94.3%
4.34%
+200.4%
OCX BuyONCOCYTE CORPORATION$15,886,000
-5.0%
7,564,934
+110.3%
2.31%
-1.0%
DAL SellDELTA AIR LINES INC DELput$10,962,000
-21.7%
200,000
-20.0%
1.59%
-18.3%
AST  ASTERIAS BIOTHERAPEUTICS INC$7,674,000
-35.6%
5,292,1560.0%1.12%
-32.8%
BA ExitBOEING COput$0-110,000
-100.0%
-4.52%
Other managers

Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):

Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2018-05-15
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
STAAR SURGICAL CO42Q3 202359.1%
MONSTER BEVERAGE CORP NEW34Q3 202349.7%
ISHARES TR33Q3 202314.8%
ONCOCYTE CORPORATION31Q2 20234.6%
BIOTIME INC25Q2 201917.8%
AXON ENTERPRISE INC24Q3 202313.4%
AGEX THERAPEUTICS INC20Q3 20231.5%
LINEAGE CELL THERAPEUTICS INC17Q3 20235.1%
ASTERIAS BIOTHERAPEUTICS INC16Q4 20182.9%
CYNOSURE INC15Q4 201610.4%

View BROADWOOD CAPITAL INC's complete holdings history.

Latest filings
TypeFiled
42024-04-15
13F-HR2024-02-14
42024-02-08
42024-01-10
42024-01-05
42023-11-30
13F-HR2023-11-14
42023-11-14
42023-11-09
42023-11-06

View BROADWOOD CAPITAL INC's complete filings history.

Compare quarters

Export BROADWOOD CAPITAL INC's holdings